The era of pandemic-era blockbuster revenues at BioNTech has come to a definitive end. The Mainz-based biotech is shuttering four ...
The first half of May is shaping up as a critical inflection point for BioNTech, with the German biotech facing ...
The narrative around BioNTech has shifted decisively. The pandemic-era cash cow is fading, and the company is now racing to ...
The German biotech has clawed back more than 22 percent from its March nadir of €72.50, closing Friday at €88.75. ...
The rally in BioNTech shares this month has been one of the sector's standout stories, but a hefty insider sale ...
The narrative around BioNTech is undergoing a quiet but decisive shift. While the Mainz-based biotech’s legacy COVID-19 vaccine business sputters, ...
The numbers tell a stark story of transition. BioNTech’s Covid vaccine revenue is sliding toward a projected €2.0-2.3 billion for ...
The clock is ticking for BioNTech. After a 30-day rally that has pushed its stock up 23% to €92.70, the ...
The numbers coming out of BioNTech’s pancreatic cancer study are the kind that make oncologists sit up. Seven out of ...
A resurgence in biotech sentiment, driven by sector-wide deal speculation and clinical breakthroughs, is providing a powerful tailwind for BioNTech ...
